Does tralokinumab have a higher rate of conjunctivitis versus dupilumab?
Featuring Tina Bhutani-Jacques, MD, MAS |
CEO, Synergy Dermatology
Associate Clinical Professor of Dermatology
University of California, SF
San Francisco, CA
Related Media
Powered by Polaris TM